Comparison · NCT00975000-sae
Cinacalcet vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cinacalcet vs Placebo: serious adverse events. Trial comparisons, record NCT00975000-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00975000-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.263 | 0.166 | 0.39 | wilson | |
| Risk in group 2 | 0.333 | 0.225 | 0.463 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0702 | -0.232 | 0.0965 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.789 | 0.447 | 1.39 | log | |
| Odds ratio, group 1 over group 2 | 0.714 | 0.319 | 1.6 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Cinacalcet than on Placebo | 14.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cinacalcet | Participants received cinacalcet at a starting dose of 30 mg orally once daily for 52 weeks. Cinacalcet dose was titrated every 4 weeks during the dose-titration phase and during study visits in the maintenance phase based on the iPTH values, corrected total serum calcium values, and safety assessments. | 15 | 57 | EG001 |
| Group 2 | Placebo | Participants received placebo orally once daily for 52 weeks. | 19 | 57 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 60 Weeks
Source ClinicalTrials.gov
Trial
- Title
- Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
- NCT number
- NCT00975000
- Phases
- PHASE3
- Conditions
Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
- Interventions
- Cinacalcet, Placebo
- Lead sponsor
- Amgen
- Results first posted
- 2016-01-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00975000?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00975000-sae